Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) CEO Harith Rajagopalan acquired 25,000 shares of Fractyl Health stock in a transaction on Wednesday, June 10th. The shares were bought at an average price of $0.73 per share, for a total transaction of $18,250.00. Following the purchase, the chief executive officer owned 540,557 shares of the company’s stock, valued at $394,606.61. This represents a 4.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Fractyl Health Trading Down 1.1%
Shares of GUTS opened at $0.72 on Friday. The stock’s 50-day moving average is $0.69 and its two-hundred day moving average is $1.07. The stock has a market cap of $114.85 million, a PE ratio of -0.56 and a beta of 2.34. Fractyl Health, Inc. has a 12 month low of $0.38 and a 12 month high of $2.45. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. Equities analysts forecast that Fractyl Health, Inc. will post -0.6 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Fractyl Health
Institutional Trading of Fractyl Health
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new stake in Fractyl Health in the third quarter valued at about $19,298,000. 683 Capital Management LLC increased its holdings in Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after buying an additional 1,397,620 shares during the last quarter. Marshall Wace LLP increased its holdings in Fractyl Health by 234.9% in the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after buying an additional 4,156,969 shares during the last quarter. Pale Fire Capital SE increased its holdings in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after buying an additional 2,711,103 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Fractyl Health in the third quarter valued at about $8,981,000.
About Fractyl Health
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Featured Stories
- Five stocks we like better than Fractyl Health
- Build On a Strong Earnings Season With These 3 ETFs
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
